U.S. drugmaker Pfizer on Tuesday raised its full-year profit forecast on strong demand for its heart disease drug, Vyndaqel, and blood thinner, Eliquis, after its second-quarter results benefited from a weaker dollar.

Pfizer Inc. raised its profit forecast for the year, with the drugmaker’s ongoing cost cuts helping to make up for a lack of expected sales growth.The company’s stock rose 1.5% in premarket trading in New York Tuesday as investors look for good news after a decline in demand for the company’s Covid products forced the drugmaker to reshape its business.

The results come as Pfizer and other drugmakers grapple with Trump's calls to lower U.S. drug prices and brace for his planned tariffs on pharmaceuticals.